Soterios Pharma — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Soterios Pharma is a private, clinical-stage biotech developing topical dermatology treatments, with a lead program (STS-01) for mild-to-moderate alopecia areata that has completed a Phase II trial. The company's strategy centers on repurposing or optimizing mechanisms with established safety profiles to create convenient, topical therapies for underserved dermatology indications. Led by an experienced team with pharmaceutical industry and startup expertise, and advised by notable figures including Shire's founder, Soterios is positioned to address a significant market gap where current systemic therapies like JAK inhibitors have limitations.

Dermatology

Technology Platform

A 'de-risked' development approach focusing on repurposing or optimizing pharmacological mechanisms with established safety profiles in dermatology into optimized topical formulations for underserved indications.

Opportunities

The primary opportunity is addressing the large, completely untreated mild-to-moderate alopecia areata patient population (est.

400,000 in US alone) with a safe, convenient topical therapy.

The recent approval of systemic JAK inhibitors for severe AA validates the disease as a commercial priority and creates a clear market segment for a topical alternative.

Risk Factors

Key risks include clinical failure in Phase III trials, future competition from other topical therapies entering the same niche, and financial risk associated with funding late-stage development as a private company.

Execution risk in commercializing the product, potentially without a large partner, is also a consideration.

Competitive Landscape

Competition in alopecia areata is bifurcated. For severe AA, systemic JAK inhibitors (e.g., Olumiant, Litfulo) are the main competitors but are not targeted for mild disease. For Soterios's target mild-moderate segment, direct competition is currently minimal, with no approved therapies. However, other biotechs are likely developing topical JAKs and novel agents for this same opportunity, representing future competitive threats.

More companies in Small Molecule Drugs →More companies in United Kingdom →